Brief: ARS Pharmaceuticals Announces Neffy Meets Primary Endpoints And Shows Rapid Symptom Control In Phase 2 urticaria Clinical Study
26/02/2024 14:09
Feb 26 (Reuters) - ARS Pharmaceuticals Inc SPRY.O :
* ARS PHARMACEUTICALS ANNOUNCES NEFFY® MEETS PRIMARY
ENDPOINTS AND
SHOWS RAPID SYMPTOM CONTROL IN PHASE 2 URTICARIA CLINICAL STUDY
* ARS PHARMACEUTICALS: PLANNED OUTPATIENT STUDY IN ACUTE
FLARES TO
INITIATE DURING 2024, WITH PIVOTAL STUDY TO POTENTIALLY INITIATE
IN 2025
Source text for Eikon: ID:nGNX43MHXb
Further company coverage: SPRY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle